News

MySize's Bold Steps Towards Sustainable Fashion Growth

MySize's Bold Steps Towards Sustainable Fashion Growth

MySize Takes a Strategic Leap in the Fashion Industry

In a significant move that aligns with the European Union's push for sustainable apparel, MySize has made headway with its acquisition of Percentil. This acquisition not only strengthens MySize's market position but also taps into the evolving circular fashion economy.

Enhanced Market Positioning through Percentil

MySize is now better positioned to thrive in a landscape shaped by new EU legislation that mandates durability, repairability, recyclability, and traceability in the apparel sector. The company's founder, Ronen Luzon, emphasized their commitment to generating long-term value while consistently making operational advancements.

"The EU is redefining the fashion industry's rules, and Percentil will aid brands in adhering to these fresh regulations while opening up novel paths for growth," Luzon remarked.

Q2 and H1 2025 Performance Overview

MySize disclosed key financial metrics for the second quarter and the first half of 2025, showcasing a strategic approach to navigating the market. The firm reported a revenue of $2.0 million for Q2, reflecting a 2% YoY increase, driven primarily by the Percentil acquisition. However, revenue for the first half decreased by 30% to $3.5 million, attributed to challenges with Orgad's sales amidst shifting market dynamics.

  • Gross Profit: The corporation reported a gross profit of $1.1 million for Q2, which is a 14% increase year-over-year, whereas gross profit for H1 was recorded at $1.5 million, down by 30% YoY.
  • Operating Loss Reduction: Operating losses improved to $586,000 in Q2, marking a substantial 49% improvement compared to the same period in 2024.
  • Healthy Cash Position: MySize maintained a solid cash position of $4.28 million as of June 30, 2025, along with $2.90 million in inventory.
  • Contribution from Percentil: Since its acquisition in May, Percentil has contributed $180,000 in revenue, with integration milestones achieving faster-than-expected progress.
  • Optimization Strategies: MySize's transition to Fulfillment by Amazon (FBA) has effectively lowered logistics costs while enhancing delivery efficiency.

Transformative Impact of Percentil

Percentil plays a pivotal role in the circular fashion economy throughout Europe. The company's platform simplifies compliance with EU regulations that compel brands to manage the full lifecycle of their products, including take-back, recycling, and repair. This shift is not merely a trend; it's a significant industry transformation propelled by both regulation and consumer demand for sustainable practices.

Percentil's capabilities in AI-driven product matching, garment grading, and logistics integration make it an invaluable asset for brands navigating this landscape. Luzon pointed out that while some firms may perceive regulation as a challenge, MySize views it as a competitive edge.

Future Growth and Strategic Focus

Looking forward, MySize is dedicated to capturing long-term marketing opportunities in the European resale sector. The company anticipates an accelerated contribution from Percentil in the latter part of 2025, spurred by partnerships with brands and an increasing demand for regulatory compliance. This proactive approach positions MySize to harness operational synergies and sustainable cash flow moving ahead.

About MySize, Inc.

MySize, Inc. (NASDAQ: MYSZ) specializes in AI-powered fashion technology, offering solutions encompassing sizing, e-commerce, and circular fashion platforms. With subsidiaries like Orgad—a fashion e-commerce venture—and Percentil, MySize empowers retailers to enhance conversion rates and minimize returns while contributing to sustainable commerce. The company’s innovations, including the FirstLook Smart Mirror and Smart Catalog, facilitate personalization for customers in both online and in-store environments.

Investor Relations and Updates

Investors can find critical updates on the Investor Relations section of the MySize website. The company actively engages with stakeholders through social media platforms, including Facebook, LinkedIn, Instagram, and X.

Frequently Asked Questions

What is MySize's latest acquisition?

MySize has acquired Percentil to enhance its presence in the circular fashion economy.

How did MySize perform in Q2 2025?

In Q2 2025, MySize reported a revenue of $2.0 million, up 2% year-over-year.

What is the focus of Percentil?

Percentil focuses on helping brands comply with EU regulations concerning the lifecycle of products in the fashion industry.

What future plans does MySize have?

MySize plans to increase its capabilities and output through the Percentil acquisition and regulatory compliance.

How can investors stay updated on MySize?

Investors can follow updates through the MySize Investor Relations website and their social media channels.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 230

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 225

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
DIRECTV Bags New NHL Deals: Stakes for Sports Fans

Updated Category News Views 308

NHL Fans, Strap in: DIRECTV Expands Its Lineup In a world where keeping up with your favorite team gets tougher each day, DIRECTV just lobbed a puck right into the net with their latest play. They've snagged a multi-year deal with the NHL for the Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues networks. It's a game changer, folks. If you...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 412

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
Firefox Champions Privacy with Iconic Internet Campaign

Updated Category News Views 106

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 130

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 288

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
CapCut's Role in AI-Assisted Small Biz Marketing

Updated Category News Views 131

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...

Continue Reading
Ivonescimab Promises New Hope for Advanced BTC Patients

Updated Category News Views 127

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 134

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading

Top 5 Most Recently Viewed Articles

Expanding Horizons: Future of IVD Contract Manufacturing

Updated Category News Views 117

The Growing Landscape of IVD Contract Manufacturing The in vitro diagnostics (IVD) contract manufacturing market is on the brink of significant expansion, anticipated to reach a staggering USD 39.74 billion by 2031. This growth represents a compounded annual growth rate (CAGR) of 11.60% from 2024 to 2031, driven chiefly by the needs of the healthcare industry to keep pace...

Continue Reading
Citi Upgrades AerCap Holdings Price Target to $117 Amid Strong Performance

Updated Category News Views 79

Citi Upgrades AerCap Holdings Price Target Citi has recently updated its outlook on AerCap Holdings (NYSE:AER), raising the price target to $117 from $113. This move reflects Citi's confident stance on the aircraft leasing company's financial health within the aviation sector. By reaffirming their buy rating, the firm signals strong expectations for AerCap's growth...

Continue Reading
LG Energy Solution Reports Strong Q2 2025 Financial Performance

Updated Category News Views 750

LG Energy Solution Achieves Remarkable Financial Milestones In a significant announcement, LG Energy Solution has revealed its performance for the second quarter of 2025, detailing impressive results that demonstrate the company's resilience and strategic focus on growth. With consolidated revenue of KRW 5.6 trillion and an operating profit of KRW 492.2 billion, the...

Continue Reading
Genpact Shines as a Leader in Sustainability Recognition

Updated Category News Views 264

Genpact's Sustainable Initiatives Gain Global Recognition Recently, Genpact (NYSE: G), an advanced technology services provider, received significant acclaim for its commitment to sustainability. Being featured in TIME's prestigious list of the World's Best Companies in Sustainable Growth for 2025 showcases their dedication to ethical business practices and innovation. A...

Continue Reading
Medical Express Ambulance Faces Data Breach Investigation

Updated Category News Views 344

Understanding the Data Breach Investigation Edelson Lechtzin LLP, a prominent class action law firm, is currently looking into data privacy concerns affecting customers of Medical Express Ambulance, Inc. (MedEx). MedEx has reported potential unauthorized access to its network, raising significant alarm regarding the safety of customer data. Medical Express Ambulance, Inc....

Continue Reading